JP2019525915A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019525915A5 JP2019525915A5 JP2019500509A JP2019500509A JP2019525915A5 JP 2019525915 A5 JP2019525915 A5 JP 2019525915A5 JP 2019500509 A JP2019500509 A JP 2019500509A JP 2019500509 A JP2019500509 A JP 2019500509A JP 2019525915 A5 JP2019525915 A5 JP 2019525915A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pulmonary
- hypertension
- disorders
- syndrome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 27
- 150000001875 compounds Chemical class 0.000 claims 16
- 201000010099 disease Diseases 0.000 claims 15
- 208000035475 disorder Diseases 0.000 claims 11
- 208000002815 pulmonary hypertension Diseases 0.000 claims 9
- 208000006011 Stroke Diseases 0.000 claims 7
- 230000001154 acute effect Effects 0.000 claims 7
- 230000002685 pulmonary effect Effects 0.000 claims 7
- 206010012289 Dementia Diseases 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 206010019280 Heart failures Diseases 0.000 claims 5
- 206010020772 Hypertension Diseases 0.000 claims 5
- 208000001647 Renal Insufficiency Diseases 0.000 claims 5
- 230000001684 chronic effect Effects 0.000 claims 5
- 210000002216 heart Anatomy 0.000 claims 5
- 201000006370 kidney failure Diseases 0.000 claims 5
- 208000004296 neuralgia Diseases 0.000 claims 5
- 208000021722 neuropathic pain Diseases 0.000 claims 5
- 208000011580 syndromic disease Diseases 0.000 claims 5
- 208000031229 Cardiomyopathies Diseases 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 4
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 4
- 150000001768 cations Chemical class 0.000 claims 4
- 208000010877 cognitive disease Diseases 0.000 claims 4
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 claims 4
- 230000006378 damage Effects 0.000 claims 4
- 206010012601 diabetes mellitus Diseases 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 4
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 4
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 4
- 230000002093 peripheral effect Effects 0.000 claims 4
- 201000011461 pre-eclampsia Diseases 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 230000002792 vascular Effects 0.000 claims 4
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 3
- 206010003694 Atrophy Diseases 0.000 claims 3
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 3
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 3
- 208000006029 Cardiomegaly Diseases 0.000 claims 3
- 201000003883 Cystic fibrosis Diseases 0.000 claims 3
- 206010014561 Emphysema Diseases 0.000 claims 3
- 206010019196 Head injury Diseases 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 3
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 3
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 3
- 208000033626 Renal failure acute Diseases 0.000 claims 3
- 230000037444 atrophy Effects 0.000 claims 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims 3
- 208000020832 chronic kidney disease Diseases 0.000 claims 3
- 230000003511 endothelial effect Effects 0.000 claims 3
- 208000010706 fatty liver disease Diseases 0.000 claims 3
- 208000014674 injury Diseases 0.000 claims 3
- 208000028867 ischemia Diseases 0.000 claims 3
- 208000017169 kidney disease Diseases 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 208000030159 metabolic disease Diseases 0.000 claims 3
- 208000010125 myocardial infarction Diseases 0.000 claims 3
- 230000000414 obstructive effect Effects 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 125000003341 7 membered heterocyclic group Chemical group 0.000 claims 2
- 201000001320 Atherosclerosis Diseases 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- 206010003671 Atrioventricular Block Diseases 0.000 claims 2
- 201000006474 Brain Ischemia Diseases 0.000 claims 2
- 206010006482 Bronchospasm Diseases 0.000 claims 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000028698 Cognitive impairment Diseases 0.000 claims 2
- 206010011796 Cystitis interstitial Diseases 0.000 claims 2
- 206010013496 Disturbance in attention Diseases 0.000 claims 2
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims 2
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 2
- 208000005189 Embolism Diseases 0.000 claims 2
- 208000004248 Familial Primary Pulmonary Hypertension Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 108010028554 LDL Cholesterol Proteins 0.000 claims 2
- 208000005777 Lupus Nephritis Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 206010027525 Microalbuminuria Diseases 0.000 claims 2
- 208000034486 Multi-organ failure Diseases 0.000 claims 2
- 206010030113 Oedema Diseases 0.000 claims 2
- 208000002193 Pain Diseases 0.000 claims 2
- 206010063985 Phytosterolaemia Diseases 0.000 claims 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 claims 2
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 claims 2
- 201000001068 Prinzmetal angina Diseases 0.000 claims 2
- 208000010378 Pulmonary Embolism Diseases 0.000 claims 2
- 208000003782 Raynaud disease Diseases 0.000 claims 2
- 208000002227 Sitosterolemia Diseases 0.000 claims 2
- 208000001435 Thromboembolism Diseases 0.000 claims 2
- 208000032594 Vascular Remodeling Diseases 0.000 claims 2
- 201000004810 Vascular dementia Diseases 0.000 claims 2
- 208000009729 Ventricular Premature Complexes Diseases 0.000 claims 2
- 206010065341 Ventricular tachyarrhythmia Diseases 0.000 claims 2
- 208000027418 Wounds and injury Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 230000005856 abnormality Effects 0.000 claims 2
- 201000011040 acute kidney failure Diseases 0.000 claims 2
- 125000002723 alicyclic group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 claims 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 238000002399 angioplasty Methods 0.000 claims 2
- 206010002906 aortic stenosis Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 230000001746 atrial effect Effects 0.000 claims 2
- 230000007885 bronchoconstriction Effects 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 206010008118 cerebral infarction Diseases 0.000 claims 2
- 238000002512 chemotherapy Methods 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229940109239 creatinine Drugs 0.000 claims 2
- 230000007812 deficiency Effects 0.000 claims 2
- 230000007850 degeneration Effects 0.000 claims 2
- 238000000502 dialysis Methods 0.000 claims 2
- 230000003205 diastolic effect Effects 0.000 claims 2
- 230000004064 dysfunction Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 208000006575 hypertriglyceridemia Diseases 0.000 claims 2
- 201000001881 impotence Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000007232 portal hypertension Diseases 0.000 claims 2
- 208000028173 post-traumatic stress disease Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 210000001147 pulmonary artery Anatomy 0.000 claims 2
- 230000009467 reduction Effects 0.000 claims 2
- 230000000241 respiratory effect Effects 0.000 claims 2
- 208000037803 restenosis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 201000000980 schizophrenia Diseases 0.000 claims 2
- 208000007056 sickle cell anemia Diseases 0.000 claims 2
- 231100000240 steatosis hepatitis Toxicity 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 238000002054 transplantation Methods 0.000 claims 2
- 208000019553 vascular disease Diseases 0.000 claims 2
- 230000002861 ventricular Effects 0.000 claims 2
- 206010047302 ventricular tachycardia Diseases 0.000 claims 2
- KKJUPNGICOCCDW-UHFFFAOYSA-N 7-N,N-Dimethylamino-1,2,3,4,5-pentathiocyclooctane Chemical compound CN(C)C1CSSSSSC1 KKJUPNGICOCCDW-UHFFFAOYSA-N 0.000 claims 1
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010001580 Albuminuria Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010002199 Anaphylactic shock Diseases 0.000 claims 1
- 206010002329 Aneurysm Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010002915 Aortic valve incompetence Diseases 0.000 claims 1
- 206010003130 Arrhythmia supraventricular Diseases 0.000 claims 1
- 200000000007 Arterial disease Diseases 0.000 claims 1
- 206010003175 Arterial spasm Diseases 0.000 claims 1
- 206010003658 Atrial Fibrillation Diseases 0.000 claims 1
- 208000002102 Atrial Premature Complexes Diseases 0.000 claims 1
- 206010003662 Atrial flutter Diseases 0.000 claims 1
- 208000006808 Atrioventricular Nodal Reentry Tachycardia Diseases 0.000 claims 1
- 206010061666 Autonomic neuropathy Diseases 0.000 claims 1
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims 1
- 208000020925 Bipolar disease Diseases 0.000 claims 1
- 206010071445 Bladder outlet obstruction Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000004990 Cardiorenal syndrome Diseases 0.000 claims 1
- 206010048610 Cardiotoxicity Diseases 0.000 claims 1
- 206010059109 Cerebral vasoconstriction Diseases 0.000 claims 1
- 208000026151 Chronic thromboembolic pulmonary hypertension Diseases 0.000 claims 1
- 206010053567 Coagulopathies Diseases 0.000 claims 1
- 208000029147 Collagen-vascular disease Diseases 0.000 claims 1
- 208000014526 Conduction disease Diseases 0.000 claims 1
- 208000002330 Congenital Heart Defects Diseases 0.000 claims 1
- 208000004117 Congenital Myasthenic Syndromes Diseases 0.000 claims 1
- 206010010356 Congenital anomaly Diseases 0.000 claims 1
- 208000019886 Congenital renal disease Diseases 0.000 claims 1
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims 1
- 206010052895 Coronary artery insufficiency Diseases 0.000 claims 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 208000016192 Demyelinating disease Diseases 0.000 claims 1
- 206010012305 Demyelination Diseases 0.000 claims 1
- 206010012335 Dependence Diseases 0.000 claims 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010052337 Diastolic dysfunction Diseases 0.000 claims 1
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 201000009273 Endometriosis Diseases 0.000 claims 1
- 206010048554 Endothelial dysfunction Diseases 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000007530 Essential hypertension Diseases 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000004930 Fatty Liver Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000021663 Female sexual arousal disease Diseases 0.000 claims 1
- 206010057671 Female sexual dysfunction Diseases 0.000 claims 1
- 102000008946 Fibrinogen Human genes 0.000 claims 1
- 108010049003 Fibrinogen Proteins 0.000 claims 1
- 206010070538 Gestational hypertension Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000022461 Glomerular disease Diseases 0.000 claims 1
- 108010010234 HDL Lipoproteins Proteins 0.000 claims 1
- 102000015779 HDL Lipoproteins Human genes 0.000 claims 1
- 206010019708 Hepatic steatosis Diseases 0.000 claims 1
- 208000007514 Herpes zoster Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 206010020575 Hyperammonaemia Diseases 0.000 claims 1
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 1
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 1
- 206010020852 Hypertonia Diseases 0.000 claims 1
- 206010020853 Hypertonic bladder Diseases 0.000 claims 1
- 206010021036 Hyponatraemia Diseases 0.000 claims 1
- 206010058558 Hypoperfusion Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010021133 Hypoventilation Diseases 0.000 claims 1
- 206010021143 Hypoxia Diseases 0.000 claims 1
- 208000024934 IgG4-related mediastinitis Diseases 0.000 claims 1
- 206010021639 Incontinence Diseases 0.000 claims 1
- 206010061216 Infarction Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 1
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 claims 1
- 208000006264 Korsakoff syndrome Diseases 0.000 claims 1
- 206010049694 Left Ventricular Dysfunction Diseases 0.000 claims 1
- 206010024119 Left ventricular failure Diseases 0.000 claims 1
- 201000002832 Lewy body dementia Diseases 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- 108090001030 Lipoproteins Proteins 0.000 claims 1
- 102000004895 Lipoproteins Human genes 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000008771 Lymphadenopathy Diseases 0.000 claims 1
- 206010025219 Lymphangioma Diseases 0.000 claims 1
- 208000002805 Mediastinal fibrosis Diseases 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000011682 Mitral valve disease Diseases 0.000 claims 1
- 206010027727 Mitral valve incompetence Diseases 0.000 claims 1
- 208000016285 Movement disease Diseases 0.000 claims 1
- 208000002038 Muscle Hypertonia Diseases 0.000 claims 1
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 claims 1
- 206010029279 Neurogenic bladder Diseases 0.000 claims 1
- 208000007125 Neurotoxicity Syndromes Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000036576 Obstructive uropathy Diseases 0.000 claims 1
- 208000009722 Overactive Urinary Bladder Diseases 0.000 claims 1
- 206010033799 Paralysis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000000450 Pelvic Pain Diseases 0.000 claims 1
- 206010034487 Pericarditis constrictive Diseases 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 206010061340 Peripheral embolism Diseases 0.000 claims 1
- 208000018262 Peripheral vascular disease Diseases 0.000 claims 1
- 208000008601 Polycythemia Diseases 0.000 claims 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims 1
- 208000000418 Premature Cardiac Complexes Diseases 0.000 claims 1
- 208000031467 Pulmonary capillary hemangiomatosis Diseases 0.000 claims 1
- 206010037423 Pulmonary oedema Diseases 0.000 claims 1
- 206010037457 Pulmonary vasculitis Diseases 0.000 claims 1
- 208000014777 Pulmonary venoocclusive disease Diseases 0.000 claims 1
- 206010063837 Reperfusion injury Diseases 0.000 claims 1
- 208000017442 Retinal disease Diseases 0.000 claims 1
- 206010038923 Retinopathy Diseases 0.000 claims 1
- 201000007981 Reye syndrome Diseases 0.000 claims 1
- 206010039163 Right ventricular failure Diseases 0.000 claims 1
- 201000004239 Secondary hypertension Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims 1
- 208000003734 Supraventricular Tachycardia Diseases 0.000 claims 1
- 206010071436 Systolic dysfunction Diseases 0.000 claims 1
- 208000001871 Tachycardia Diseases 0.000 claims 1
- 208000001163 Tangier disease Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 208000018452 Torsade de pointes Diseases 0.000 claims 1
- 208000002363 Torsades de Pointes Diseases 0.000 claims 1
- 206010044221 Toxic encephalopathy Diseases 0.000 claims 1
- 231100000076 Toxic encephalopathy Toxicity 0.000 claims 1
- 206010060872 Transplant failure Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 201000001943 Tricuspid Valve Insufficiency Diseases 0.000 claims 1
- 206010044640 Tricuspid valve incompetence Diseases 0.000 claims 1
- 206010044642 Tricuspid valve stenosis Diseases 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 1
- 208000003800 Urinary Bladder Neck Obstruction Diseases 0.000 claims 1
- 206010046914 Vaginal infection Diseases 0.000 claims 1
- 201000008100 Vaginitis Diseases 0.000 claims 1
- 208000009325 Variant Angina Pectoris Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 208000008131 Ventricular Flutter Diseases 0.000 claims 1
- 206010047281 Ventricular arrhythmia Diseases 0.000 claims 1
- 201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 claims 1
- 201000008803 Wolff-Parkinson-white syndrome Diseases 0.000 claims 1
- 206010048215 Xanthomatosis Diseases 0.000 claims 1
- 230000035508 accumulation Effects 0.000 claims 1
- 238000009825 accumulation Methods 0.000 claims 1
- 230000004913 activation Effects 0.000 claims 1
- 206010069351 acute lung injury Diseases 0.000 claims 1
- 208000012998 acute renal failure Diseases 0.000 claims 1
- 208000013228 adenopathy Diseases 0.000 claims 1
- 230000002776 aggregation Effects 0.000 claims 1
- 238000004220 aggregation Methods 0.000 claims 1
- 230000001476 alcoholic effect Effects 0.000 claims 1
- 208000033571 alveolar capillary dysplasia with misalignment of pulmonary veins Diseases 0.000 claims 1
- -1 amine compound Chemical class 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 230000002491 angiogenic effect Effects 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 201000002064 aortic valve insufficiency Diseases 0.000 claims 1
- 230000037007 arousal Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000037849 arterial hypertension Diseases 0.000 claims 1
- 210000002565 arteriole Anatomy 0.000 claims 1
- 210000001367 artery Anatomy 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 208000015294 blood coagulation disease Diseases 0.000 claims 1
- 230000036765 blood level Effects 0.000 claims 1
- 230000036772 blood pressure Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000014633 carbohydrates Nutrition 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 206010007625 cardiogenic shock Diseases 0.000 claims 1
- 231100000259 cardiotoxicity Toxicity 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 208000015114 central nervous system disease Diseases 0.000 claims 1
- 230000002490 cerebral effect Effects 0.000 claims 1
- 230000003788 cerebral perfusion Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 claims 1
- 208000028831 congenital heart disease Diseases 0.000 claims 1
- 208000018631 connective tissue disease Diseases 0.000 claims 1
- 208000000839 constrictive pericarditis Diseases 0.000 claims 1
- 238000007887 coronary angioplasty Methods 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000007547 defect Effects 0.000 claims 1
- 201000009101 diabetic angiopathy Diseases 0.000 claims 1
- 230000005750 disease progression Effects 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- 230000008694 endothelial dysfunction Effects 0.000 claims 1
- 230000005713 exacerbation Effects 0.000 claims 1
- 230000029142 excretion Effects 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 229940012952 fibrinogen Drugs 0.000 claims 1
- 235000013305 food Nutrition 0.000 claims 1
- 210000001652 frontal lobe Anatomy 0.000 claims 1
- 230000001434 glomerular Effects 0.000 claims 1
- 206010061989 glomerulosclerosis Diseases 0.000 claims 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 claims 1
- 230000036541 health Effects 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 208000007386 hepatic encephalopathy Diseases 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 125000005842 heteroatom Chemical group 0.000 claims 1
- 201000005991 hyperphosphatemia Diseases 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 208000018875 hypoxemia Diseases 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 208000001286 intracranial vasospasm Diseases 0.000 claims 1
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 230000028252 learning or memory Effects 0.000 claims 1
- 230000003902 lesion Effects 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 201000002818 limb ischemia Diseases 0.000 claims 1
- 230000006372 lipid accumulation Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000003141 lower extremity Anatomy 0.000 claims 1
- 206010025005 lumbar spinal stenosis Diseases 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 201000001231 mediastinitis Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 230000005012 migration Effects 0.000 claims 1
- 238000013508 migration Methods 0.000 claims 1
- 208000027061 mild cognitive impairment Diseases 0.000 claims 1
- 208000006887 mitral valve stenosis Diseases 0.000 claims 1
- 210000001616 monocyte Anatomy 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 210000004165 myocardium Anatomy 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 230000004112 neuroprotection Effects 0.000 claims 1
- 229910052757 nitrogen Inorganic materials 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 208000020629 overactive bladder Diseases 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 244000045947 parasite Species 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 230000008447 perception Effects 0.000 claims 1
- 230000010412 perfusion Effects 0.000 claims 1
- 230000035699 permeability Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 229910052700 potassium Inorganic materials 0.000 claims 1
- 239000011591 potassium Substances 0.000 claims 1
- 230000036316 preload Effects 0.000 claims 1
- 206010036596 premature ejaculation Diseases 0.000 claims 1
- 238000004321 preservation Methods 0.000 claims 1
- 208000037920 primary disease Diseases 0.000 claims 1
- 201000008312 primary pulmonary hypertension Diseases 0.000 claims 1
- 230000000750 progressive effect Effects 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 208000005333 pulmonary edema Diseases 0.000 claims 1
- 201000010298 pulmonary valve insufficiency Diseases 0.000 claims 1
- 208000009138 pulmonary valve stenosis Diseases 0.000 claims 1
- 208000037813 pulmonary venous hypertension Diseases 0.000 claims 1
- 208000030390 pulmonic stenosis Diseases 0.000 claims 1
- 230000010451 regulation of platelet aggregation Effects 0.000 claims 1
- 230000010410 reperfusion Effects 0.000 claims 1
- 208000015658 resistant hypertension Diseases 0.000 claims 1
- 230000029058 respiratory gaseous exchange Effects 0.000 claims 1
- 201000004409 schistosomiasis Diseases 0.000 claims 1
- 208000037812 secondary pulmonary hypertension Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 230000001568 sexual effect Effects 0.000 claims 1
- 230000036299 sexual function Effects 0.000 claims 1
- 230000035939 shock Effects 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 230000000391 smoking effect Effects 0.000 claims 1
- 210000002460 smooth muscle Anatomy 0.000 claims 1
- 208000005198 spinal stenosis Diseases 0.000 claims 1
- 230000007863 steatosis Effects 0.000 claims 1
- 210000004003 subcutaneous fat Anatomy 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 206010042772 syncope Diseases 0.000 claims 1
- 230000006794 tachycardia Effects 0.000 claims 1
- 230000000542 thalamic effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000002537 thrombolytic effect Effects 0.000 claims 1
- 230000001732 thrombotic effect Effects 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 230000000472 traumatic effect Effects 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
- 210000001635 urinary tract Anatomy 0.000 claims 1
- 201000002327 urinary tract obstruction Diseases 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 210000003462 vein Anatomy 0.000 claims 1
- 208000003663 ventricular fibrillation Diseases 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022010212A JP7368516B2 (ja) | 2016-07-07 | 2022-01-26 | ｓＧＣ刺激剤のリンプロドラッグ |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662359419P | 2016-07-07 | 2016-07-07 | |
| US62/359,419 | 2016-07-07 | ||
| PCT/US2017/040809 WO2018009596A1 (en) | 2016-07-07 | 2017-07-06 | Phosphorus prodrugs of sgc stimulators |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022010212A Division JP7368516B2 (ja) | 2016-07-07 | 2022-01-26 | ｓＧＣ刺激剤のリンプロドラッグ |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019525915A JP2019525915A (ja) | 2019-09-12 |
| JP2019525915A5 true JP2019525915A5 (OSRAM) | 2020-08-13 |
| JP7016853B2 JP7016853B2 (ja) | 2022-02-07 |
Family
ID=59351139
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019500509A Active JP7016853B2 (ja) | 2016-07-07 | 2017-07-06 | ｓＧＣ刺激剤のリンプロドラッグ |
| JP2022010212A Active JP7368516B2 (ja) | 2016-07-07 | 2022-01-26 | ｓＧＣ刺激剤のリンプロドラッグ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022010212A Active JP7368516B2 (ja) | 2016-07-07 | 2022-01-26 | ｓＧＣ刺激剤のリンプロドラッグ |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US10927136B2 (OSRAM) |
| EP (1) | EP3481837B1 (OSRAM) |
| JP (2) | JP7016853B2 (OSRAM) |
| KR (1) | KR102513343B1 (OSRAM) |
| CN (2) | CN114736240A (OSRAM) |
| AU (2) | AU2017291826B2 (OSRAM) |
| BR (1) | BR112019000290B1 (OSRAM) |
| CA (1) | CA3029374A1 (OSRAM) |
| EA (1) | EA039683B1 (OSRAM) |
| IL (1) | IL263993B2 (OSRAM) |
| MA (1) | MA45592A (OSRAM) |
| MX (2) | MX391896B (OSRAM) |
| WO (1) | WO2018009596A1 (OSRAM) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7016853B2 (ja) * | 2016-07-07 | 2022-02-07 | サイクレリオン・セラピューティクス，インコーポレーテッド | ｓＧＣ刺激剤のリンプロドラッグ |
| CA3103676A1 (en) | 2018-07-11 | 2020-01-16 | Cyclerion Therapeutics, Inc. | Use of sgc stimulators for the treatment of mitochonrial disorders |
| CN114377149B (zh) * | 2021-12-14 | 2023-11-10 | 西北工业大学 | 一种Mn基可降解MOF纳米反应器及其制备方法和应用 |
| CA3273101A1 (en) * | 2022-11-07 | 2024-05-16 | Illexcor Holdings, Llc. | Benzaldehyde compounds with direct polymer destabilizing effects for the treatment of sickle cell disease |
| CN116478309B (zh) * | 2023-05-19 | 2024-05-17 | 青海大学 | 锁阳精多糖、锁阳多糖化合物及制备方法和应用 |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5721365A (en) | 1989-09-15 | 1998-02-24 | Us Health | N-substituted piperazine NONOates |
| US5155137A (en) | 1990-09-20 | 1992-10-13 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Complexes of nitric oxide with polyamines |
| EP0605622B1 (en) | 1991-09-24 | 1997-11-12 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Oxygen substituted derivatives of nucleophile-nitric oxide adducts as nitric oxide donor prodrugs |
| US5814666A (en) | 1992-04-13 | 1998-09-29 | The United States As Represented By The Department Of Health And Human Services | Encapsulated and non-encapsulated nitric oxide generators used as antimicrobial agents |
| US5405919A (en) | 1992-08-24 | 1995-04-11 | The United States Of America As Represented By The Secretary Of Health And Human Services | Polymer-bound nitric oxide/nucleophile adduct compositions, pharmaceutical compositions and methods of treating biological disorders |
| US5910316A (en) | 1992-08-24 | 1999-06-08 | The United States Of America, As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents to treat impotency |
| US5691423A (en) | 1992-08-24 | 1997-11-25 | The United States Of America As Represented By The Department Of Health And Human Services | Polysaccharide-bound nitric oxide-nucleophile adducts |
| US5632981A (en) | 1992-08-24 | 1997-05-27 | The United States Of America As Represented By The Department Of Health And Human Services | Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same |
| US5650442A (en) | 1993-10-08 | 1997-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide releasing compounds as hypoxic cell radiation sensitizers |
| JP2928079B2 (ja) | 1994-02-14 | 1999-07-28 | 永信薬品工業股▲ふん▼有限公司 | １−（置換ベンジル）−３−（置換アリール）縮合ピラゾール類、その製造法及びその用途 |
| US5700830A (en) | 1994-11-22 | 1997-12-23 | The United States Of America As Represented By The Department Of Health And Human Services | Use of nitric oxide-releasing agents for reducing metastasis risk |
| NZ310559A (en) | 1995-06-21 | 1999-05-28 | Shionogi & Co | Bicyclic sulphonamide and carboxamide derivatives and medicaments |
| US5714511A (en) | 1995-07-31 | 1998-02-03 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Selective prevention of organ injury in sepsis and shock using selection release of nitric oxide in vulnerable organs |
| JP4120993B2 (ja) | 1996-12-12 | 2008-07-16 | 塩野義製薬株式会社 | ヘテロ環縮合ベンゼンカルボン酸アミド誘導体およびそれを含有するｐｇｄ２拮抗剤 |
| BR9714016A (pt) | 1996-12-13 | 2000-02-29 | Shionogi & Co | Derivados de benzotiofenocarboxamida e antagonistas a pgd2, que compreendem os mesmos |
| DE19744026A1 (de) | 1997-10-06 | 1999-04-08 | Hoechst Marion Roussel De Gmbh | Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln |
| DE19830430A1 (de) | 1998-07-08 | 2000-01-13 | Hoechst Marion Roussel De Gmbh | Schwefelsubstituierte Sulfonylamino-carbonsäure-N-arylamide, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate |
| CZ302691B6 (cs) | 1998-07-08 | 2011-09-07 | Sanofi - Aventis Deutschland GmbH | N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| GB9824310D0 (en) | 1998-11-05 | 1998-12-30 | Univ London | Activators of soluble guanylate cyclase |
| DE19942809A1 (de) | 1999-09-08 | 2001-03-15 | Bayer Ag | Verfahren zur Herstellung substituierter Pyrimidinderivate |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| US20010051624A1 (en) | 2000-04-12 | 2001-12-13 | Jones Thomas R. | Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists |
| ATE311200T1 (de) | 2000-04-12 | 2005-12-15 | Merck Frosst Canada Inc | Verfahren und zusammensetzungen zur behandlung von allergischen zuständen mit pgd2 rezeptor antagonisten |
| US6878522B2 (en) | 2000-07-07 | 2005-04-12 | Baiyong Li | Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2 |
| AR035431A1 (es) | 2001-02-13 | 2004-05-26 | Aventis Pharma Gmbh | 6,7,8,9-tetrahidro-5h-benzocicloheptenil aminas aciladas, un metodo para su sintesis, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos |
| TWI241190B (en) | 2001-02-13 | 2005-10-11 | Aventis Pharma Gmbh | 4-Fluoro-N-indan-2-yl benzamide and its use as pharmaceutical |
| TWI243164B (en) | 2001-02-13 | 2005-11-11 | Aventis Pharma Gmbh | Acylated indanyl amines and their use as pharmaceuticals |
| PE20020856A1 (es) | 2001-02-13 | 2002-11-11 | Aventis Pharma Gmbh | 1,2,3,4-tetrahidronaftil aminas aciladas |
| US6511911B1 (en) | 2001-04-03 | 2003-01-28 | Advanced Micro Devices, Inc. | Metal gate stack with etch stop layer |
| KR20040044856A (ko) | 2001-09-07 | 2004-05-31 | 오노 야꾸힝 고교 가부시키가이샤 | 인돌 유도체 화합물 |
| US7153852B2 (en) | 2001-09-07 | 2006-12-26 | Ono Pharmaceutical Co., Ltd. | Indole compounds, process for producing the same and drugs containing the same as the active ingredient |
| SE0200411D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| SE0200356D0 (sv) | 2002-02-05 | 2002-02-05 | Astrazeneca Ab | Novel use |
| DE10216145A1 (de) | 2002-04-12 | 2003-10-23 | Bayer Ag | Verwendung von Stimulatoren der löslichen Guanylatcyclase zur Behandlung von Glaukom |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| US7534897B2 (en) | 2002-05-16 | 2009-05-19 | Shionogi & Co., Ltd. | Indole arylsulfonaimide compounds exhibiting PGD 2 receptor antagonism |
| JPWO2003097042A1 (ja) | 2002-05-16 | 2005-09-15 | 塩野義製薬株式会社 | Ｐｇｄ２受容体拮抗剤 |
| TW200307542A (en) | 2002-05-30 | 2003-12-16 | Astrazeneca Ab | Novel compounds |
| SE0201635D0 (sv) | 2002-05-30 | 2002-05-30 | Astrazeneca Ab | Novel compounds |
| SE0202241D0 (sv) | 2002-07-17 | 2002-07-17 | Astrazeneca Ab | Novel Compounds |
| EP1556047A4 (en) | 2002-10-04 | 2009-09-30 | Millennium Pharm Inc | ANTAGONISTS AGAINST THE PGD2 RECEPTOR FOR THE TREATMENT OF INFLAMMATORY DISEASES |
| ES2401079T3 (es) | 2002-12-20 | 2013-04-16 | Amgen Inc. | Moduladores del asma y de la inflamación alérgica |
| US8309608B2 (en) | 2003-11-06 | 2012-11-13 | Sanofi-Aventis Deutschland Gmbh | Use of eNOS transcription enhancers in the cell therapy of ischemic heart diseases |
| CN101346390B (zh) * | 2005-12-27 | 2011-11-09 | 大塚制药株式会社 | 水溶性苯并氮杂*化合物及其药物组合物 |
| DE102007036075A1 (de) * | 2007-08-01 | 2009-02-05 | Bayer Healthcare Ag | Prodrugs und ihre Verwendung |
| CA2698332C (en) | 2007-09-06 | 2012-08-21 | Merck Sharp & Dohme Corp. | Pyrazole derivatives as soluble guanylate cyclase activators |
| CA2711134A1 (en) | 2008-01-24 | 2009-07-30 | Merck Sharp & Dohme Corp. | Angiotensin ii receptor antagonists |
| CN101735267A (zh) * | 2008-11-17 | 2010-06-16 | 上海阳帆医药科技有限公司 | 水溶性(r)-(-)-比卡鲁胺前药、其制备方法及用途 |
| EP2373317B1 (en) | 2008-11-25 | 2016-12-14 | Merck Sharp & Dohme Corp. | 4-amino-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one or 4-amino-5,8-dihydropyrido[2,3-d]pyrimidin-7(6H)-one derivatives as activators of the soluble guanylat cyclase for the treatment of cardiovascular diseases |
| WO2010099054A2 (en) | 2009-02-26 | 2010-09-02 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| EP2549875B1 (en) | 2010-03-25 | 2015-05-13 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| MA34330B1 (fr) | 2010-05-27 | 2013-06-01 | Merck Sharp & Dohme | Activateurs de guanylate cyclase soluble |
| EP2632551B1 (en) | 2010-10-28 | 2016-07-06 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| SG191946A1 (en) * | 2011-01-14 | 2013-08-30 | Vertex Pharma | Pyrimidine gyrase and topoisomerase iv inhibitors |
| CN103288809B (zh) * | 2012-02-24 | 2015-09-23 | 深圳市健元医药科技有限公司 | 葛根素单磷酸盐或单磺酸盐衍生物及其制备方法 |
| CA2907111C (en) * | 2013-03-15 | 2023-10-24 | Joel Moore | Sgc stimulators |
| KR101749314B1 (ko) * | 2013-03-29 | 2017-07-03 | 수안주 파마 코포레이션 리미티드 | 비사이클릭-치환된 피리미딘 타입 pde-5 억제제의 프로드러그 |
| EP3094327A1 (en) * | 2014-01-13 | 2016-11-23 | Ironwood Pharmaceuticals, Inc. | USE OF sGC STIMULATORS FOR THE TREATMENT OF NEUROMUSCULAR DISORDERS |
| JP7016853B2 (ja) * | 2016-07-07 | 2022-02-07 | サイクレリオン・セラピューティクス，インコーポレーテッド | ｓＧＣ刺激剤のリンプロドラッグ |
-
2017
- 2017-07-06 JP JP2019500509A patent/JP7016853B2/ja active Active
- 2017-07-06 CN CN202111570967.XA patent/CN114736240A/zh active Pending
- 2017-07-06 EP EP17740237.7A patent/EP3481837B1/en active Active
- 2017-07-06 AU AU2017291826A patent/AU2017291826B2/en active Active
- 2017-07-06 WO PCT/US2017/040809 patent/WO2018009596A1/en not_active Ceased
- 2017-07-06 CA CA3029374A patent/CA3029374A1/en active Pending
- 2017-07-06 MX MX2019000103A patent/MX391896B/es unknown
- 2017-07-06 US US16/315,210 patent/US10927136B2/en active Active
- 2017-07-06 BR BR112019000290-1A patent/BR112019000290B1/pt active IP Right Grant
- 2017-07-06 KR KR1020197003458A patent/KR102513343B1/ko active Active
- 2017-07-06 CN CN201780045937.2A patent/CN109476686B/zh active Active
- 2017-07-06 EA EA201990238A patent/EA039683B1/ru unknown
- 2017-07-06 MA MA045592A patent/MA45592A/fr unknown
-
2018
- 2018-12-27 IL IL263993A patent/IL263993B2/en unknown
-
2019
- 2019-01-07 MX MX2022005024A patent/MX2022005024A/es unknown
-
2022
- 2022-01-19 AU AU2022200331A patent/AU2022200331B2/en active Active
- 2022-01-26 JP JP2022010212A patent/JP7368516B2/ja active Active
-
2023
- 2023-09-01 US US18/241,630 patent/US20240228520A9/en not_active Abandoned
-
2024
- 2024-01-12 US US18/411,480 patent/US20240360164A1/en not_active Abandoned
- 2024-11-14 US US18/947,131 patent/US20250243228A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019525915A5 (OSRAM) | ||
| JP2019524710A5 (OSRAM) | ||
| JP2016540017A5 (OSRAM) | ||
| HRP20200276T1 (hr) | Stimulatori sgc | |
| JP2016517432A5 (OSRAM) | ||
| JP6823095B2 (ja) | 噴霧乾燥製剤 | |
| HRP20211355T1 (hr) | Fuzionirani biciklični sgc stimulatori | |
| CN107406421A (zh) | sGC刺激物 | |
| JP2013533250A5 (ja) | 環縮合４−アミノピリミジンおよび可溶性グアニル酸シクラーゼの刺激剤としてのその使用 | |
| JP2019526582A5 (OSRAM) | ||
| JP2017527604A5 (OSRAM) | ||
| US20190255042A1 (en) | Application of hedgehog pathway inhibitor in treating fibrosis diseases | |
| JP2012532112A5 (OSRAM) | ||
| JP2016530210A (ja) | ヘテロ環式ビニルオートタキシン阻害剤化合物 | |
| CN102050888B (zh) | 一种依诺肝素钠的制备方法 | |
| JP2023504415A (ja) | 線維性疾患の治療に使用するためのアゼチジンｌｐａ１受容体アンタゴニストのピルフェニドン及び／又はニンテダニブとの合剤 | |
| JP2014513077A (ja) | 線維症、疼痛、癌、ならびに呼吸器、アレルギー性、神経系または心血管疾患の治療に有用な３−または５−ビフェニル−４−イルイソキサゾールに基づく化合物 | |
| TWI272263B (en) | PGD2/TXA2 two receptors antagonistic pharmaceutical composition having [2,2,1] and [3,1,1] bicyclo skeleton | |
| CN102256984B (zh) | 制备二胺衍生物的方法 | |
| CN105085428B (zh) | 芳杂环类衍生物及其在药物上的应用 | |
| JP2014525427A5 (OSRAM) | ||
| JP2019526589A5 (OSRAM) | ||
| CN113260616B (zh) | 用于治疗呼吸系统疾病的新型化合物 | |
| RS61999B1 (sr) | Jedinjenja | |
| WO2025011664A1 (zh) | Glp-1r激动剂的制剂及其制备方法 |